Table 3.
Seroprevalence of antibodies against SARS-CoV-2 in various countries and cities.
| Location | Seroprevalence (%)1 | N2 | Reference |
|---|---|---|---|
| Iran | 22.89 | 5877 | (203) |
|
Switzerland
Geneva |
7.58 10.8 |
16758 775 |
(203) (204) |
|
United Kingdom
London |
6.94 13 |
182072 9547 |
(203) (205) |
|
Sweden
Stockholm |
5.6 11.5 |
1200 >1003 |
(206) |
|
USA
New York City |
4.89 19.5 |
4.89 1581 |
(203) (207) |
|
Spain
Madrid |
4.66 11.3 |
1018251 3186 |
(203) (208) |
| France | 2.78 | 5534 | (203) |
| Netherlands | 2.77 | 36791 | (203) |
| Brazil | 1.29 | 157360 | (203) |
|
Canada
Montreal Toronto Vancouver |
1.06 3.05 1.5 0.55 |
50269 7691 1837 885 |
(203) (209) (210) (211) |
|
Italy
Milan |
1.04 5.2 |
904 789 |
(203) (212) |
|
China
Wuhan |
0.8 2.29 |
10449 17794 |
(203) (213) |
|
Iceland
Reykjavik |
0.3 0.4 |
18609 4843 |
(135) |
A sampling of published SARS-CoV-2 seroprevalence studies are listed below to demonstrate the wide range of values observed around the world and relatively low worldwide seropositivity.
1Reported seroprevalences reflect the most recent data available, although some values are from as early as April 2020.
2Sample sizes for data from SeroTracker (203) are summations of the “N” column values for all relevant studies included at the time of publication;
3The exact sample size was not reported, simply that it was greater than 100.